The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Respiratory Drugs Market Research Report 2024
Synopsis
Respiratory drug is a term used to describe a wide variety of medicines used to relieve, treat, or prevent respiratory diseases such as asthma, chronic bronchitis, chronic obstructive pulmonary disease (COPD), or pneumonia.
The global Respiratory Drugs market was valued at US$ 43040 million in 2023 and is anticipated to reach US$ 64390 million by 2030, witnessing a CAGR of 5.8% during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Respiratory Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Respiratory Drugs.
Report Scope
The Respiratory Drugs market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Respiratory Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Respiratory Drugs companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Allied Healthcare
Cardinal Health
Medtronic
Drager Medical
DeVilbiss Healthcare
Fisher & Paykel Healthcare
Getinge
Hamilton Medical
Invacare Corporation
nSpire Health
ResMed
Respironics
Segment by Type
Asthma
Chronic Obstructive Pulmonary Disease
Idiopathic Pulmonary Fibrosis
Cystic Fibrosis
Segment by Application
Hospitals
Ambulatory Care
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Respiratory Drugs companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Respiratory drug is a term used to describe a wide variety of medicines used to relieve, treat, or prevent respiratory diseases such as asthma, chronic bronchitis, chronic obstructive pulmonary disease (COPD), or pneumonia.
The global Respiratory Drugs market was valued at US$ 43040 million in 2023 and is anticipated to reach US$ 64390 million by 2030, witnessing a CAGR of 5.8% during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Respiratory Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Respiratory Drugs.
Report Scope
The Respiratory Drugs market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Respiratory Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Respiratory Drugs companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Allied Healthcare
Cardinal Health
Medtronic
Drager Medical
DeVilbiss Healthcare
Fisher & Paykel Healthcare
Getinge
Hamilton Medical
Invacare Corporation
nSpire Health
ResMed
Respironics
Segment by Type
Asthma
Chronic Obstructive Pulmonary Disease
Idiopathic Pulmonary Fibrosis
Cystic Fibrosis
Segment by Application
Hospitals
Ambulatory Care
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Respiratory Drugs companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Respiratory Drugs Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Asthma
1.2.3 Chronic Obstructive Pulmonary Disease
1.2.4 Idiopathic Pulmonary Fibrosis
1.2.5 Cystic Fibrosis
1.3 Market by Application
1.3.1 Global Respiratory Drugs Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Hospitals
1.3.3 Ambulatory Care
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Respiratory Drugs Market Perspective (2019-2030)
2.2 Respiratory Drugs Growth Trends by Region
2.2.1 Global Respiratory Drugs Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Respiratory Drugs Historic Market Size by Region (2019-2024)
2.2.3 Respiratory Drugs Forecasted Market Size by Region (2025-2030)
2.3 Respiratory Drugs Market Dynamics
2.3.1 Respiratory Drugs Industry Trends
2.3.2 Respiratory Drugs Market Drivers
2.3.3 Respiratory Drugs Market Challenges
2.3.4 Respiratory Drugs Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Respiratory Drugs Players by Revenue
3.1.1 Global Top Respiratory Drugs Players by Revenue (2019-2024)
3.1.2 Global Respiratory Drugs Revenue Market Share by Players (2019-2024)
3.2 Global Respiratory Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Respiratory Drugs Revenue
3.4 Global Respiratory Drugs Market Concentration Ratio
3.4.1 Global Respiratory Drugs Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Respiratory Drugs Revenue in 2023
3.5 Respiratory Drugs Key Players Head office and Area Served
3.6 Key Players Respiratory Drugs Product Solution and Service
3.7 Date of Enter into Respiratory Drugs Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Respiratory Drugs Breakdown Data by Type
4.1 Global Respiratory Drugs Historic Market Size by Type (2019-2024)
4.2 Global Respiratory Drugs Forecasted Market Size by Type (2025-2030)
5 Respiratory Drugs Breakdown Data by Application
5.1 Global Respiratory Drugs Historic Market Size by Application (2019-2024)
5.2 Global Respiratory Drugs Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Respiratory Drugs Market Size (2019-2030)
6.2 North America Respiratory Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Respiratory Drugs Market Size by Country (2019-2024)
6.4 North America Respiratory Drugs Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Respiratory Drugs Market Size (2019-2030)
7.2 Europe Respiratory Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Respiratory Drugs Market Size by Country (2019-2024)
7.4 Europe Respiratory Drugs Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Respiratory Drugs Market Size (2019-2030)
8.2 Asia-Pacific Respiratory Drugs Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Respiratory Drugs Market Size by Region (2019-2024)
8.4 Asia-Pacific Respiratory Drugs Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Respiratory Drugs Market Size (2019-2030)
9.2 Latin America Respiratory Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Respiratory Drugs Market Size by Country (2019-2024)
9.4 Latin America Respiratory Drugs Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Respiratory Drugs Market Size (2019-2030)
10.2 Middle East & Africa Respiratory Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Respiratory Drugs Market Size by Country (2019-2024)
10.4 Middle East & Africa Respiratory Drugs Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Allied Healthcare
11.1.1 Allied Healthcare Company Detail
11.1.2 Allied Healthcare Business Overview
11.1.3 Allied Healthcare Respiratory Drugs Introduction
11.1.4 Allied Healthcare Revenue in Respiratory Drugs Business (2019-2024)
11.1.5 Allied Healthcare Recent Development
11.2 Cardinal Health
11.2.1 Cardinal Health Company Detail
11.2.2 Cardinal Health Business Overview
11.2.3 Cardinal Health Respiratory Drugs Introduction
11.2.4 Cardinal Health Revenue in Respiratory Drugs Business (2019-2024)
11.2.5 Cardinal Health Recent Development
11.3 Medtronic
11.3.1 Medtronic Company Detail
11.3.2 Medtronic Business Overview
11.3.3 Medtronic Respiratory Drugs Introduction
11.3.4 Medtronic Revenue in Respiratory Drugs Business (2019-2024)
11.3.5 Medtronic Recent Development
11.4 Drager Medical
11.4.1 Drager Medical Company Detail
11.4.2 Drager Medical Business Overview
11.4.3 Drager Medical Respiratory Drugs Introduction
11.4.4 Drager Medical Revenue in Respiratory Drugs Business (2019-2024)
11.4.5 Drager Medical Recent Development
11.5 DeVilbiss Healthcare
11.5.1 DeVilbiss Healthcare Company Detail
11.5.2 DeVilbiss Healthcare Business Overview
11.5.3 DeVilbiss Healthcare Respiratory Drugs Introduction
11.5.4 DeVilbiss Healthcare Revenue in Respiratory Drugs Business (2019-2024)
11.5.5 DeVilbiss Healthcare Recent Development
11.6 Fisher & Paykel Healthcare
11.6.1 Fisher & Paykel Healthcare Company Detail
11.6.2 Fisher & Paykel Healthcare Business Overview
11.6.3 Fisher & Paykel Healthcare Respiratory Drugs Introduction
11.6.4 Fisher & Paykel Healthcare Revenue in Respiratory Drugs Business (2019-2024)
11.6.5 Fisher & Paykel Healthcare Recent Development
11.7 Getinge
11.7.1 Getinge Company Detail
11.7.2 Getinge Business Overview
11.7.3 Getinge Respiratory Drugs Introduction
11.7.4 Getinge Revenue in Respiratory Drugs Business (2019-2024)
11.7.5 Getinge Recent Development
11.8 Hamilton Medical
11.8.1 Hamilton Medical Company Detail
11.8.2 Hamilton Medical Business Overview
11.8.3 Hamilton Medical Respiratory Drugs Introduction
11.8.4 Hamilton Medical Revenue in Respiratory Drugs Business (2019-2024)
11.8.5 Hamilton Medical Recent Development
11.9 Invacare Corporation
11.9.1 Invacare Corporation Company Detail
11.9.2 Invacare Corporation Business Overview
11.9.3 Invacare Corporation Respiratory Drugs Introduction
11.9.4 Invacare Corporation Revenue in Respiratory Drugs Business (2019-2024)
11.9.5 Invacare Corporation Recent Development
11.10 nSpire Health
11.10.1 nSpire Health Company Detail
11.10.2 nSpire Health Business Overview
11.10.3 nSpire Health Respiratory Drugs Introduction
11.10.4 nSpire Health Revenue in Respiratory Drugs Business (2019-2024)
11.10.5 nSpire Health Recent Development
11.11 ResMed
11.11.1 ResMed Company Detail
11.11.2 ResMed Business Overview
11.11.3 ResMed Respiratory Drugs Introduction
11.11.4 ResMed Revenue in Respiratory Drugs Business (2019-2024)
11.11.5 ResMed Recent Development
11.12 Respironics
11.12.1 Respironics Company Detail
11.12.2 Respironics Business Overview
11.12.3 Respironics Respiratory Drugs Introduction
11.12.4 Respironics Revenue in Respiratory Drugs Business (2019-2024)
11.12.5 Respironics Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest IT & Electronics Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
